|
|
Post by BlueCat on Feb 3, 2016 18:05:43 GMT -5
There are a few points that seem mismatch:
1. Can they or can't they? On one hand, sounds like they can do nothing until April 5. Yet, they are talking with potential regional partners? I thought they weren't allowed to talk?
2. What does this mean for the third-party clinics? Is the SNY departure going to be transparent to their business?
3. If they cannot do anything til SNY returns rights and SNY isn't doing enough to sell, then, why would they ask to delay the return? Costs will go up faster than revenue?
Overall, I thought the clarification was ok. Lack of news, not so much. They really need to be able to disclose something about RLS.
Not quite the clobbering I was hoping for. Too much uncertainty about how they are going to make the bills near term.
|
|
|
|
Post by dreamboatcruise on Feb 3, 2016 18:05:46 GMT -5
I'd add the one that really disappointed me... no discussions with payers until after the transition... i.e. MNKD won't even get a perspective on probability of getting better coverage until Q2. Are they going to decide to reduce the price without even having these discussions? Maybe reducing to SQ RAA level is no brainer... but I can't imagine payers would adjust formulary just based on change in price if MNKD isn't talking to them.
|
|
|
|
Post by od on Feb 3, 2016 18:08:30 GMT -5
I'd add the one that really disappointed me... no discussions with payers until after the transition... i.e. MNKD won't even get a perspective on probability of getting better coverage until Q2. Are they going to decide to reduce the price without even having these discussions? Maybe reducing to SQ RAA level is no brainer... but I can't imagine payers would adjust formulary just based on change in price if MNKD isn't talking to them. I would like to think Matt has engaged best-in-class specialists to advise on and execute payor negotiations. |
|
|
|
Post by dreamboatcruise on Feb 3, 2016 18:08:49 GMT -5
I was wondering this as well, can't SNY stop any efforts associated with 'A until the deal ends in April? Also, would the clinics offer up different options for the basal insulins... hmm To be regulatory compliant, the centers will need to offer all therapies for diabetes. There certainly would be issues of whether payers would allow them to be in network if they only offered treatment that the payers didn't want to cover, but are there really regulations against not offering some therapies? That would seem odd. For example, here in Cali you go to one doctor if you want to medicate with Oxycontin and a different doc if you want to medicate with pot... they don't require that every doc offer both... I (oops) people have to drive around to both when they've made poor investing choices. |
|
|
|
Post by seanismorris on Feb 3, 2016 18:09:52 GMT -5
I've looked into RLS's previous company name...found nothing.
Does anyone have their actual address? I think a Google street view has a good chance of showing the old company name. Assuming it's posted on the building...
|
|
|
|
Post by BlueCat on Feb 3, 2016 18:11:19 GMT -5
I'd add the one that really disappointed me... no discussions with payers until after the transition... i.e. MNKD won't even get a perspective on probability of getting better coverage until Q2. Are they going to decide to reduce the price without even having these discussions? Maybe reducing to SQ RAA level is no brainer... but I can't imagine payers would adjust formulary just based on change in price if MNKD isn't talking to them. I would like to think Matt has engaged best-in-class specialists to advise on and execute payor negotiations. I think that's another point that would have been helpful to understand. Matt took time to say what they couldn't do while waiting for the transfer (that they may ask to delay?)- it would have been helpful to hear more about what they can do right now. Laying the foundation of what they can immediately execute on as soon as they do have control, or what like the clinics, doesn't have to wait on that. Net - I'm actually a little more confused in a few areas. |
|
|
|
Post by sccrbrg on Feb 3, 2016 18:11:37 GMT -5
Thought a pilot in Jersey was schedule to start this month (Feb). Looks like that got bumped back. Horrible call overall. We would have been significantly better off with no update. Basically a rehash of the JPM conference - except that bankruptcy was mentioned umpteen times and described as "not a possibility at this time" which is verbatim what they said about SNY splitting. Also, confirmed that absolutely nothing is going to happen with afrezza until April other than the afrezza clinics. And we'll probably take another hammering on the quarterly earnings call. They most likely just sunk us back to .50. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Feb 3, 2016 18:13:22 GMT -5
Anyone hear Matt is not taking increase in pay? Thats very admirable
|
|
|
|
Post by trenddiver on Feb 3, 2016 18:13:23 GMT -5
Much to say about nothing. My prediction is more downgrades or reconfirming bearish position by Goldman, Piper, and JP Morgan. The fact that Matt said "we're not considering bankruptcy at this time" will just provide more fodder for the short interest. But that's Matt. He always makes at least one stupid statement on the CC's, unless he's intentionally trying to sandbag the SP (which I doubt).
Trend
|
|
|
|
Post by nemzter on Feb 3, 2016 18:14:17 GMT -5
To be regulatory compliant, the centers will need to offer all therapies for diabetes. There certainly would be issues of whether payers would allow them to be in network if they only offered treatment that the payers didn't want to cover, but are there really regulations against not offering some therapies? That would seem odd. Yeah I didn't think there would be any regulations, since these are so called "Afrezza" clinics, I'm sure they wouldn't offer a competing prandial as an option but push for 'A all the way! And as for basal, I would hope that they bury lantus/toujeo with tresiba as the "preferred" option  |
|
|
|
Post by dreamboatcruise on Feb 3, 2016 18:14:42 GMT -5
I think that's another point that would have been helpful to understand. Matt took time to say what they couldn't do while waiting for the transfer (that they may ask to delay?)- it would have been helpful to hear more about what they can do right now. Laying the foundation of what they can immediately execute on as soon as they do have control, or what like the clinics, doesn't have to wait on that. Net - I'm actually a little more confused in a few areas. Yes... yes! absolutely, yes. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Feb 3, 2016 18:15:17 GMT -5
I was wondering this as well, can't SNY stop any efforts associated with 'A until the deal ends in April? Also, would the clinics offer up different options for the basal insulins... hmm To be regulatory compliant, the centers will need to offer all therapies for diabetes. I feel like the clinics are the option for the spirometry, avoiding a conservative ENDO who is more afraid of a lawsuit then helping the patient, and education from diabetics using Afrezza |
|
|
|
Post by od on Feb 3, 2016 18:15:41 GMT -5
To be regulatory compliant, the centers will need to offer all therapies for diabetes. There certainly would be issues of whether payers would allow them to be in network if they only offered treatment that the payers didn't want to cover, but are there really regulations against not offering some therapies? That would seem odd. Providers must prescribe what they think is in the best interest of the patient's health. Of course, providers all have there go-tos... |
|
|
|
Post by dreamboatcruise on Feb 3, 2016 18:17:08 GMT -5
There certainly would be issues of whether payers would allow them to be in network if they only offered treatment that the payers didn't want to cover, but are there really regulations against not offering some therapies? That would seem odd. Yeah I didn't think there would be any regulations, since these are so called "Afrezza" clinics, I'm sure they wouldn't offer a competing prandial as an option but push for 'A all the way! And as for basal, I would hope that they bury lantus/toujeo with tresiba as the "preferred" option The only thing is... I still don't see how the clinic manages to pay the staff. It would seem no insurer is going to put them in network, if they openly say they plan to prescribe something that the insurers don't won't to pay for. Fewer and fewer people are on insurance plans where they can go to whomever they wish. |
|
|
|
Post by cathode on Feb 3, 2016 18:18:40 GMT -5
I've looked into RLS's previous company name...found nothing. Does anyone have their actual address? I think a Google street view has a good chance of showing the old company name. Assuming it's posted on the building... There is a thread that has been devoted to information finding regarding RLS. Here is the RLS threadIt would be nice to keep that in one thread, I think. Still, we know very little. The address of the governing persons is a residential address, so it is likely not HQ. Google Street Viewwww.sos.wa.gov/corps/search_detail.aspx?ubi=603568334 |
|
